Glenmark Pharmaceuticals, having navigated recent challenges, is shifting its focus to branded products for higher profit margins. The company, aiming for a 12%-15% growth rate, divested its active pharmaceutical ingredient business to concentrate on branded pharmaceuticals, particularly in respiratory, dermatology, and oncology.
